NASDAQ:OTLK Oncobiologics (OTLK) Stock Price, News & Analysis $1.70 -0.13 (-7.10%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$1.78 +0.08 (+4.41%) As of 04:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Oncobiologics Stock (NASDAQ:OTLK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Oncobiologics alerts:Sign Up Key Stats Today's Range$1.69▼$1.8750-Day Range$0.22▼$1.8352-Week Range$0.16▼$3.39Volume10.70 million shsAverage Volume45.88 million shsMarket Capitalization$238.09 millionP/E RatioN/ADividend YieldN/APrice Target$6.50Consensus RatingHold Company Overview Oncobiologics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation. Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary. This global footprint enables the company to conduct end-to-end process development and scale-up operations, optimizing both development timelines and production costs in major biopharmaceutical markets. The company’s pipeline comprises multiple biosimilar candidates targeting established therapies in oncology and supportive care, with programs at various stages of preclinical and clinical development. Oncobiologics advances its portfolio through a disciplined clinical strategy and selective partnerships designed to streamline regulatory pathways. By focusing on broadening patient access to proven biologic medicines, the company seeks to address unmet needs in the United States, Europe and other global regions with its upcoming biosimilar products.AI Generated. May Contain Errors. Read More Oncobiologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreOTLK MarketRank™: Oncobiologics scored higher than 71% of companies evaluated by MarketBeat, and ranked 191st out of 850 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingOncobiologics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 5 hold ratings, and 1 sell rating.Upside PotentialOncobiologics has a consensus price target of $6.50, representing about 282.4% upside from its current price of $1.70.Amount of Analyst CoverageOncobiologics has only been the subject of 3 research reports in the past 90 days.Read more about Oncobiologics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Oncobiologics are expected to grow in the coming year, from ($0.48) to ($0.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncobiologics is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncobiologics is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Oncobiologics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.73% of the float of Oncobiologics has been sold short.Short Interest Ratio / Days to CoverOncobiologics has a short interest ratio ("days to cover") of 0.25, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oncobiologics has recently increased by 77.52%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOncobiologics does not currently pay a dividend.Dividend GrowthOncobiologics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.67 News SentimentOncobiologics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Oncobiologics this week, compared to 2 articles on an average week.Search Interest44 people have searched for OTLK on MarketBeat in the last 30 days. This is an increase of 2,100% compared to the previous 30 days.MarketBeat Follows18 people have added Oncobiologics to their MarketBeat watchlist in the last 30 days. This is an increase of 1,700% compared to the previous 30 days. Company Ownership3.8 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Oncobiologics in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $5,062,498.00 in company stock, which represents 2.1263% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Oncobiologics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,062,498.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders1.80% of the stock of Oncobiologics is held by insiders.Percentage Held by Institutions11.20% of the stock of Oncobiologics is held by institutions.Read more about Oncobiologics' insider trading history. Receive OTLK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncobiologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OTLK Stock News HeadlinesOncobiologics (NASDAQ:OTLK) Upgraded to Hold at Wall Street ZenJune 20, 2026 | americanbankingnews.comOutlook Therapeutics Eye Drug Review Returns To FDA For Fourth TimeJune 17, 2026 | benzinga.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing. | Profits Run (Ad)Q3 EPS Estimates for Oncobiologics Boosted by AnalystJune 15, 2026 | americanbankingnews.comOutlook Therapeutics: Potential Catalysts Offering An Arbitrage OpportunityJune 6, 2026 | seekingalpha.comYezan Munther Haddadin Purchases 29,000 Shares of Oncobiologics (NASDAQ:OTLK) StockJune 4, 2026 | insidertrades.comOncobiologics (NASDAQ:OTLK) Director Buys $5,038,428.31 in StockJune 2, 2026 | insidertrades.comOutlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)June 1, 2026 | globenewswire.comSee More Headlines OTLK Stock Analysis - Frequently Asked Questions How have OTLK shares performed this year? Oncobiologics' stock was trading at $1.58 at the beginning of the year. Since then, OTLK stock has increased by 7.6% and is now trading at $1.70. How were Oncobiologics' earnings last quarter? Oncobiologics, Inc. (NASDAQ:OTLK) issued its quarterly earnings results on Friday, May, 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.04. The business earned $0.13 million during the quarter, compared to analysts' expectations of $4.39 million. When did Oncobiologics' stock split? Oncobiologics's stock reverse split on the morning of Thursday, March 14th 2024.The 1-20 reverse split was announced on Thursday, March 14th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Oncobiologics? Shares of OTLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oncobiologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncobiologics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Moderna (MRNA), Intel (INTC) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings5/15/2026Today6/23/2026Next Earnings (Estimated)8/13/2026Fiscal Year End9/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4w+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 For the last 4 weeks, OTLK's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OTLK CIK1649989 Webwww.outlooktherapeutics.com Phone(609) 619-3990FaxN/AEmployees20Year Founded2011Price Target and Rating Average Price Target for Oncobiologics$6.50 High Price Target$10.00 Low Price Target$3.00 Potential Upside/Downside+282.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$62.42 million Net MarginsN/A Pretax Margin-18,772.37% Return on EquityN/A Return on Assets-291.28% Debt Debt-to-Equity RatioN/A Current Ratio0.54 Quick Ratio0.45 Sales & Book Value Annual Sales$1.35 million Price / Sales176.36 Cash FlowN/A Price / Cash FlowN/A Book Value($0.60) per share Price / Book-2.83Miscellaneous Outstanding Shares140,050,000Free Float137,526,000Market Cap$238.09 million OptionableOptionable Beta0.96 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:OTLK) was last updated on 6/24/2026 by MarketBeat.com Staff. From Our PartnersMy feud with Zohran MamdaniNearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson s...Stansberry Research | SponsoredQuick favor to ask youBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTop Banks Warn: A Strange Day is Coming to AmericaGoldman Sachs and Morgan Stanley are warning clients about a developing crisis that could suppress portfolio g...TradeSmith | SponsoredA drilling crew just broke a record nobody expectedA drilling crew in Beaver County, Utah hit 15,765 feet of solid granite in 16 days - a job the Department of E...Behind the Markets | SponsoredMillionaire trader who went 13-for-13 on Trump in 2025 now turns his attention to Elon.Hedge fund trader Larry Benedict went 13-for-13 in Q1 2025 - not a single losing trade - and finished the year...Brownstone Research | SponsoredKarp just filed Form 144On May 12, 2026, Palantir CEO Alex Karp filed to sell 585,000 shares - roughly $95.93 million. Combined with f...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncobiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncobiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
